CN104507924B - 二氢吡啶酮p1作为凝血因子xia抑制剂 - Google Patents
二氢吡啶酮p1作为凝血因子xia抑制剂 Download PDFInfo
- Publication number
- CN104507924B CN104507924B CN201380040942.6A CN201380040942A CN104507924B CN 104507924 B CN104507924 B CN 104507924B CN 201380040942 A CN201380040942 A CN 201380040942A CN 104507924 B CN104507924 B CN 104507924B
- Authority
- CN
- China
- Prior art keywords
- bases
- sides
- carbon
- alkene
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*c1c(*=C)ccc(*)c1* Chemical compound C*c1c(*=C)ccc(*)c1* 0.000 description 10
- SREWLYOZPZUBEE-UHFFFAOYSA-N C=CC(c(c(N)ccc1N)c1N)=O Chemical compound C=CC(c(c(N)ccc1N)c1N)=O SREWLYOZPZUBEE-UHFFFAOYSA-N 0.000 description 1
- OQISSLMJTNLWIL-UHFFFAOYSA-N C=CC(c1cc(Cl)ccc1-[n]1ncnc1)=O Chemical compound C=CC(c1cc(Cl)ccc1-[n]1ncnc1)=O OQISSLMJTNLWIL-UHFFFAOYSA-N 0.000 description 1
- YOOXXSPIVVXNOJ-UHFFFAOYSA-N C=CC(c1cnc[n]1Cc1ccccc1)=O Chemical compound C=CC(c1cnc[n]1Cc1ccccc1)=O YOOXXSPIVVXNOJ-UHFFFAOYSA-N 0.000 description 1
- BILMGZNIFRXFGY-UHFFFAOYSA-N CC(C)(C)OC(Nc1nccc(C(C=C)=O)c1)=O Chemical compound CC(C)(C)OC(Nc1nccc(C(C=C)=O)c1)=O BILMGZNIFRXFGY-UHFFFAOYSA-N 0.000 description 1
- GRXAQXNYXXBHBY-ZNSWJNHMSA-N CC(C)[C@H](CCC[C@@H](c1cc(-c(cccc2)c2N2)ccn1)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)C2O Chemical compound CC(C)[C@H](CCC[C@@H](c1cc(-c(cccc2)c2N2)ccn1)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)C2O GRXAQXNYXXBHBY-ZNSWJNHMSA-N 0.000 description 1
- APSOJQKYCFABML-ITNSIVGMSA-N CC(CCC[C@@H](C(C1)N=CC=C1c(ccc(C(N)=O)c1)c1N1)N(CCC(c(c(Br)ccc2Cl)c2F)=C2)C2=O)C1=O Chemical compound CC(CCC[C@@H](C(C1)N=CC=C1c(ccc(C(N)=O)c1)c1N1)N(CCC(c(c(Br)ccc2Cl)c2F)=C2)C2=O)C1=O APSOJQKYCFABML-ITNSIVGMSA-N 0.000 description 1
- SUNUOUSWUILJOO-KKFPZRRJSA-N CC(CCC[C@@H](c1nccc(-c(ccc(NC(OC)=O)c2)c2N2)c1)N1N=CC(c(c(C#N)ccc3Cl)c3F)=CC1=O)C2=O Chemical compound CC(CCC[C@@H](c1nccc(-c(ccc(NC(OC)=O)c2)c2N2)c1)N1N=CC(c(c(C#N)ccc3Cl)c3F)=CC1=O)C2=O SUNUOUSWUILJOO-KKFPZRRJSA-N 0.000 description 1
- KXQWUYPEJOVQGA-BWAHOAODSA-N CC/C=C(/C1C(NC([C@H](C)CCC[C@@H]2N(CCC(c(c(F)ccc3)c3C#N)=C3)C3=O)=O)=CC(N[O](C)OC)=CC1)\C=C2/N Chemical compound CC/C=C(/C1C(NC([C@H](C)CCC[C@@H]2N(CCC(c(c(F)ccc3)c3C#N)=C3)C3=O)=O)=CC(N[O](C)OC)=CC1)\C=C2/N KXQWUYPEJOVQGA-BWAHOAODSA-N 0.000 description 1
- CODIQFASGYRTCW-NGOKVRLYSA-N C[C@H](CCC[C@@H](c1nccc(-c(c(N2)c3)ccc3NC(NC)=O)c1)N(CCC(C1CCCCC1)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1nccc(-c(c(N2)c3)ccc3NC(NC)=O)c1)N(CCC(C1CCCCC1)=C1)C1=O)C2=O CODIQFASGYRTCW-NGOKVRLYSA-N 0.000 description 1
- IRQQHHGYQUYTOU-OLILMLBXSA-N C[C@H](CCC[C@@H](c1nccc(-c(cccc2)c2N2)c1)N(CCC(c(c(-c1c[n](C)nc1)ccc1Cl)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1nccc(-c(cccc2)c2N2)c1)N(CCC(c(c(-c1c[n](C)nc1)ccc1Cl)c1F)=C1)C1=O)C2=O IRQQHHGYQUYTOU-OLILMLBXSA-N 0.000 description 1
- XSGCKOBVZSKHPJ-DWXRJYCRSA-N C[C@H](CCC[C@@H](c1nccc(-c2ccccc2N2)c1)N(CCC(c(c(Br)ccc1C3[IH]C[IH]3)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1nccc(-c2ccccc2N2)c1)N(CCC(c(c(Br)ccc1C3[IH]C[IH]3)c1F)=C1)C1=O)C2=O XSGCKOBVZSKHPJ-DWXRJYCRSA-N 0.000 description 1
- YCBBRXBMKSZEMI-UHFFFAOYSA-N C[n]1c(C(C=C)=O)cnc1 Chemical compound C[n]1c(C(C=C)=O)cnc1 YCBBRXBMKSZEMI-UHFFFAOYSA-N 0.000 description 1
- MOLOLCJBWGUSOK-SANMLTNESA-N Cc(cc1)cc(-c2cc([C@H](CCCC34CC3)N(CCC(c(c(F)ccc3Cl)c3F)=C3)C3=O)ncc2)c1NC4=O Chemical compound Cc(cc1)cc(-c2cc([C@H](CCCC34CC3)N(CCC(c(c(F)ccc3Cl)c3F)=C3)C3=O)ncc2)c1NC4=O MOLOLCJBWGUSOK-SANMLTNESA-N 0.000 description 1
- IRAGQUIAOUCVOU-UHFFFAOYSA-N O=C1N(C(C2)(C2CCC2(CC2)C(Nc2c-3cccc2)=O)c2nccc-3c2)C=CC(c(cccc2Cl)c2F)=C1 Chemical compound O=C1N(C(C2)(C2CCC2(CC2)C(Nc2c-3cccc2)=O)c2nccc-3c2)C=CC(c(cccc2Cl)c2F)=C1 IRAGQUIAOUCVOU-UHFFFAOYSA-N 0.000 description 1
- SWPBMFWKEWBJAW-HZRSZRRBSA-N O=C1N(C(C2)([C@@H]2CCC2(CC2)C(Nc2c-3ccnc2)=O)c2nccc-3c2)C=CC(c(c(F)ccc2Cl)c2F)=C1 Chemical compound O=C1N(C(C2)([C@@H]2CCC2(CC2)C(Nc2c-3ccnc2)=O)c2nccc-3c2)C=CC(c(c(F)ccc2Cl)c2F)=C1 SWPBMFWKEWBJAW-HZRSZRRBSA-N 0.000 description 1
- DCUGIAVFQDYENJ-UHFFFAOYSA-N OC(C(c(c(Br)ccc1Cl)c1F)=C1)OC1=O Chemical compound OC(C(c(c(Br)ccc1Cl)c1F)=C1)OC1=O DCUGIAVFQDYENJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810051705.4A CN108250199B (zh) | 2012-08-03 | 2013-08-02 | 二氢吡啶酮p1作为凝血因子xia抑制剂 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679197P | 2012-08-03 | 2012-08-03 | |
| US61/679,197 | 2012-08-03 | ||
| US201361787081P | 2013-03-15 | 2013-03-15 | |
| US61/787,081 | 2013-03-15 | ||
| PCT/US2013/053416 WO2014022767A1 (en) | 2012-08-03 | 2013-08-02 | Dihydropyridone p1 as factor xia inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810051705.4A Division CN108250199B (zh) | 2012-08-03 | 2013-08-02 | 二氢吡啶酮p1作为凝血因子xia抑制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104507924A CN104507924A (zh) | 2015-04-08 |
| CN104507924B true CN104507924B (zh) | 2018-01-23 |
Family
ID=48949290
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380040942.6A Active CN104507924B (zh) | 2012-08-03 | 2013-08-02 | 二氢吡啶酮p1作为凝血因子xia抑制剂 |
| CN201810051705.4A Active CN108250199B (zh) | 2012-08-03 | 2013-08-02 | 二氢吡啶酮p1作为凝血因子xia抑制剂 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810051705.4A Active CN108250199B (zh) | 2012-08-03 | 2013-08-02 | 二氢吡啶酮p1作为凝血因子xia抑制剂 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9409908B2 (enExample) |
| EP (1) | EP2880026B1 (enExample) |
| JP (1) | JP6082463B2 (enExample) |
| KR (1) | KR20150038372A (enExample) |
| CN (2) | CN104507924B (enExample) |
| AR (1) | AR091981A1 (enExample) |
| AU (1) | AU2013296259A1 (enExample) |
| BR (1) | BR112015002081A2 (enExample) |
| CA (1) | CA2880866A1 (enExample) |
| CY (1) | CY1119004T1 (enExample) |
| DK (1) | DK2880026T3 (enExample) |
| EA (1) | EA028581B1 (enExample) |
| ES (1) | ES2623175T3 (enExample) |
| HR (1) | HRP20170506T1 (enExample) |
| HU (1) | HUE032622T2 (enExample) |
| IL (1) | IL237011A0 (enExample) |
| LT (1) | LT2880026T (enExample) |
| MX (1) | MX361759B (enExample) |
| PL (1) | PL2880026T3 (enExample) |
| PT (1) | PT2880026T (enExample) |
| RS (1) | RS55975B1 (enExample) |
| SG (1) | SG11201500271UA (enExample) |
| SI (1) | SI2880026T1 (enExample) |
| SM (1) | SMT201700240T1 (enExample) |
| TW (1) | TW201410667A (enExample) |
| UY (1) | UY34960A (enExample) |
| WO (1) | WO2014022767A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| WO2013056034A1 (en) | 2011-10-14 | 2013-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2899183B1 (en) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors |
| HRP20170784T8 (hr) | 2011-10-14 | 2018-05-18 | Bristol-Myers Squibb Company | Supstituirani spojevi tetrahidroizohinolina kao inhbitori xia faktora |
| US9315519B2 (en) | 2012-10-12 | 2016-04-19 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
| EP2906541B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| HRP20180465T1 (hr) | 2012-10-12 | 2018-05-04 | Bristol-Myers Squibb Company | Kristalni oblici inhibitora faktora xia |
| JP6479763B2 (ja) | 2013-03-25 | 2019-03-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン |
| FR3010076B1 (fr) * | 2013-09-02 | 2016-12-23 | Centre Nat De La Rech Scient - Cnrs - | Inhibiteurs de metalloproteases, leurs procedes de preparation et leurs utilisations therapeutiques |
| UY35971A (es) * | 2014-01-31 | 2015-07-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Macrociclos con grupos p2? aromáticos como inhibidores del factor xia |
| NO2760821T3 (enExample) * | 2014-01-31 | 2018-03-10 | ||
| CN107074821B (zh) | 2014-09-04 | 2020-05-22 | 百时美施贵宝公司 | 为fxia抑制剂的二酰胺大环化合物 |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| NO2721243T3 (enExample) * | 2014-10-01 | 2018-10-20 | ||
| ES2762987T3 (es) * | 2015-06-19 | 2020-05-26 | Bristol Myers Squibb Co | Macrociclos de diamida como inhibidores del factor XIA |
| JO3703B1 (ar) * | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| EP3328851B1 (en) * | 2015-07-29 | 2020-04-22 | Bristol-Myers Squibb Company | Factor xia macrocyclic inhibitors bearing alkyl or cycloalkyl p2' moieties |
| CN114874222B (zh) * | 2015-07-29 | 2025-06-06 | 百时美施贵宝公司 | 携带非芳族p2,基团的因子xia新大环 |
| WO2017023992A1 (en) | 2015-08-05 | 2017-02-09 | Bristol-Myers Squibb Company | Novel substituted glycine derived fxia inhibitors |
| US10344039B2 (en) | 2015-10-29 | 2019-07-09 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use |
| CN108430471B (zh) * | 2015-10-29 | 2021-07-09 | 默沙东公司 | 因子XIa抑制剂 |
| JP2019507167A (ja) | 2016-03-02 | 2019-03-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害活性を有するジアミド大員環 |
| TW201808908A (zh) | 2016-08-22 | 2018-03-16 | 美商默沙東藥廠 | 因子XIa抑制劑 |
| WO2018133793A1 (zh) * | 2017-01-18 | 2018-07-26 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
| WO2019011166A1 (zh) * | 2017-07-14 | 2019-01-17 | 四川科伦博泰生物医药股份有限公司 | 大环酰胺化合物及其药物组合物和用途 |
| EP3957638B1 (en) | 2019-04-16 | 2025-01-08 | China Resources Biopharmaceutical Company Limited | Macrocyclic derivatives acting as xia factor inhibitor |
| EP4006029A4 (en) | 2019-07-23 | 2023-06-21 | Medshine Discovery Inc. | MACROCYCLIC DERIVATIVES AS FACTOR XIA INHIBITORS |
| WO2021121396A1 (zh) * | 2019-12-20 | 2021-06-24 | 成都康弘药业集团股份有限公司 | 作为血浆激肽释放酶抑制剂的三环类化合物及其用途 |
| CN113004284B (zh) * | 2019-12-20 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为血浆激肽释放酶抑制剂的四环类化合物及其用途 |
| CN116133660B (zh) * | 2020-07-22 | 2025-05-02 | 詹森药业有限公司 | 可用作因子XIa抑制剂的化合物 |
| TW202515882A (zh) * | 2023-06-30 | 2025-04-16 | 大陸商深圳信立泰藥業股份有限公司 | 一種多取代的大環化合物及其製備方法與應用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| WO2000076970A2 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Serine protease inhibitors |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| SI1427415T1 (sl) | 2001-09-21 | 2009-12-31 | Bristol Myers Squibb Co | Sestavine, ki vsebujejo laktame in njihovi derivati kot inhibitorji faktorja xa |
| US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7459564B2 (en) | 2005-01-13 | 2008-12-02 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor XIa inhibitors |
| US20060183771A1 (en) | 2005-02-17 | 2006-08-17 | Seiffert Dietmar A | Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors |
| US8466295B2 (en) | 2005-12-14 | 2013-06-18 | Bristol-Myers Squibb Company | Thiophene derivatives as factor XIa inhibitors |
| CA2633252A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| WO2007070818A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| JP5342450B2 (ja) | 2006-12-15 | 2013-11-13 | ブリストル−マイヤーズ スクイブ カンパニー | 第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ |
| PE20081775A1 (es) * | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
| CN101784516B (zh) | 2007-06-13 | 2014-07-02 | 百时美施贵宝公司 | 作为凝血因子抑制剂的二肽类似物 |
| JP5537442B2 (ja) | 2008-03-13 | 2014-07-02 | ブリストル−マイヤーズ スクイブ カンパニー | 第ｘｉａ因子阻害剤としてのピリダジン誘導体 |
| PH12012501589A1 (en) * | 2010-02-11 | 2012-10-22 | Bristol Myers Squibb Co | Macrocycles as factor xia inhibitors |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) * | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| WO2013056034A1 (en) | 2011-10-14 | 2013-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| HRP20170784T8 (hr) | 2011-10-14 | 2018-05-18 | Bristol-Myers Squibb Company | Supstituirani spojevi tetrahidroizohinolina kao inhbitori xia faktora |
| EP2899183B1 (en) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors |
| JP6137193B2 (ja) | 2011-12-21 | 2017-05-31 | 小野薬品工業株式会社 | 第ＸＩａ因子阻害剤としての新規ピリジノンおよびピリミジノン誘導体 |
| JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | ３位置換プロリン誘導体 |
| GB201209138D0 (en) | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
-
2013
- 2013-08-02 CN CN201380040942.6A patent/CN104507924B/zh active Active
- 2013-08-02 SG SG11201500271UA patent/SG11201500271UA/en unknown
- 2013-08-02 BR BR112015002081A patent/BR112015002081A2/pt active Search and Examination
- 2013-08-02 TW TW102127905A patent/TW201410667A/zh unknown
- 2013-08-02 SI SI201330570A patent/SI2880026T1/sl unknown
- 2013-08-02 PT PT137476255T patent/PT2880026T/pt unknown
- 2013-08-02 HU HUE13747625A patent/HUE032622T2/en unknown
- 2013-08-02 US US14/419,002 patent/US9409908B2/en active Active
- 2013-08-02 HR HRP20170506TT patent/HRP20170506T1/hr unknown
- 2013-08-02 CN CN201810051705.4A patent/CN108250199B/zh active Active
- 2013-08-02 CA CA2880866A patent/CA2880866A1/en not_active Abandoned
- 2013-08-02 PL PL13747625T patent/PL2880026T3/pl unknown
- 2013-08-02 MX MX2015000892A patent/MX361759B/es active IP Right Grant
- 2013-08-02 ES ES13747625.5T patent/ES2623175T3/es active Active
- 2013-08-02 KR KR1020157004963A patent/KR20150038372A/ko not_active Withdrawn
- 2013-08-02 EP EP13747625.5A patent/EP2880026B1/en active Active
- 2013-08-02 RS RS20170501A patent/RS55975B1/sr unknown
- 2013-08-02 JP JP2015525622A patent/JP6082463B2/ja active Active
- 2013-08-02 UY UY0001034960A patent/UY34960A/es unknown
- 2013-08-02 WO PCT/US2013/053416 patent/WO2014022767A1/en not_active Ceased
- 2013-08-02 LT LTEP13747625.5T patent/LT2880026T/lt unknown
- 2013-08-02 SM SM20170240T patent/SMT201700240T1/it unknown
- 2013-08-02 EA EA201590277A patent/EA028581B1/ru not_active IP Right Cessation
- 2013-08-02 AU AU2013296259A patent/AU2013296259A1/en not_active Abandoned
- 2013-08-02 DK DK13747625.5T patent/DK2880026T3/en active
- 2013-08-02 AR ARP130102764A patent/AR091981A1/es unknown
-
2015
- 2015-01-29 IL IL237011A patent/IL237011A0/en unknown
-
2016
- 2016-07-08 US US15/205,059 patent/US9951071B2/en active Active
-
2017
- 2017-05-09 CY CY20171100499T patent/CY1119004T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104507924B (zh) | 二氢吡啶酮p1作为凝血因子xia抑制剂 | |
| CN106795161B (zh) | 作为因子xia抑制剂的嘧啶酮 | |
| EP2978751B1 (en) | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors | |
| DK3099688T3 (en) | MACROCYLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | |
| CN102026996B (zh) | 作为凝血因子xia抑制剂的哒嗪衍生物 | |
| CN107849026B (zh) | 携带烷基或环烷基p2′部分的因子xia大环抑制剂 | |
| CN114805365B (zh) | 携带非芳族p2′基团的因子xia新大环 | |
| HK40023053B (en) | Pyrimidinones as factor xia inhibitors | |
| HK40023053A (en) | Pyrimidinones as factor xia inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yang Wu Inventor after: SMITH II LEON M Inventor after: Smallheer Joanne M. Inventor after: Gilligan Paul J. Inventor after: PINTO DONALD J P PINTO Inventor after: Tino Joseph A. Inventor after: DILGER ANDREW K Inventor after: Wang Yufeng Inventor after: Fang Tianan Inventor after: PABBISETTY KUMAR B Inventor before: Yang Wu Inventor before: SMITH II LEON M Inventor before: Smallheer Joanne M. Inventor before: Gilligan Paul J. Inventor before: PINTO DONALD J P PINTO Inventor before: Tino Joseph A. Inventor before: DILGER ANDREW K Inventor before: Wang Yufeng Inventor before: T *fang Inventor before: PABBISETTY KUMAR B |
|
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |